Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AGN194204 (IRX4204) is inactive against RAR and is an orally active and selective RXR agonist with Kd values 0.4 nM, 3.6 nM and 3.8 nM and EC50s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 has anti-inflammatory and anticarcinogenic actions[1][2].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 12,800 | 8-10周 | ||
50 mg | ¥ 16,800 | 8-10周 | ||
100 mg | ¥ 21,500 | 8-10周 |
产品描述 | AGN194204 (IRX4204) is inactive against RAR and is an orally active and selective RXR agonist with Kd values 0.4 nM, 3.6 nM and 3.8 nM and EC50s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 has anti-inflammatory and anticarcinogenic actions[1][2]. |
靶点活性 | RXRβ:0.8 nM (EC50), RXRβ:3.6 nM (kd), RXRα:0.2 nM (EC50), RXRα:0.4 nM (kd), RXRγ:0.08 nM (EC50), RXRγ:3.8 nM (kd) |
体外活性 | AGN194204 (NRX194204; 1 μM; 72 hours; SK-BR-3 human breast cancer cells) treatment induces apoptosis in breast cancer cells[1]. AGN194204 (NRX194204; 0-100 nM; 24 hours; E, RAW cells) treatment blocks the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells[1]. |
体内活性 | AGN194204 (NRX194204; 30-60 mg/kg; oral administration; daily; for 15 weeks; female A/J mice) treatment significantly reduces the number and size of tumors on the surface of the lungs. It reduces the total tumor volume per slide by 64% to 81% compared with the control group[1]. |
别名 | IRX4204, NRX194204, VTP 194204 |
分子量 | 352.51 |
分子式 | C24H32O2 |
CAS No. | 220619-73-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AGN194204 220619-73-8 Others IRX 4204 IRX-4204 AGN-194204 IRX4204 VTP-194204 NRX194204 VTP 194204 NRX-194204 VTP194204 NRX 194204 AGN 194204 Inhibitor inhibitor inhibit